Things You Should Know

What do blood tests and critical markers measure?

Blood tests and critical markers are laboratory measures taken from a blood sample to assess body function, disease risk, or active illness. A marker is any measurable feature linked to a biological process, such as inflammation, infection, oxygen transport, kidney stress, or metabolic balance. In practice, this includes routine panels like the complete blood count (CBC), as well as targeted markers such as C-reactive protein (CRP), procalcitonin (PCT), and selected immune or metabolic signals.

For longevity, their value is not that they predict lifespan directly. Rather, they may reveal patterns tied to processes that shape aging outcomes, including chronic inflammation, poor glucose handling, organ strain, or severe infection. Human studies in acute illness show that some markers help estimate severity or short-term risk, while other uses remain exploratory. For example, blood cultures remain the reference method for confirming bloodstream infection, whereas procalcitonin (PCT) may help interpret whether bacterial infection is likely, but it does not replace culture.

A practical concept is context. A result becomes meaningful when interpreted alongside symptoms, medical history, medications, and repeat testing over time. One isolated abnormal value may reflect stress, timing, hydration, or lab variation rather than durable risk.

Why do these markers matter for long-term health?

These markers matter because they can act as early signals of physiological strain before major clinical events occur. Longevity is influenced not only by diagnosed disease, but also by the cumulative burden of inflammation, infection, oxidative stress, anemia, and metabolic disruption. Blood tests may help detect these states earlier, which can support monitoring and more informed follow-up.

Available human research shows this idea most clearly in acute care. In sepsis, inflammatory and oxidative markers such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), oxidized low-density lipoprotein (oxLDL), and glutathione (GSH) have been associated with illness severity. However, these data largely come from hospitalized patients and should not be generalized to healthy adults as direct aging markers. Likewise, metabolic biomarker panels in patients with Coronavirus Disease 2019 (COVID-19) appeared to improve prediction of in-hospital mortality in one human study, but that is prognostic evidence in critical illness, not proof of longer lifespan.

The larger principle is that repeated blood abnormalities may indicate biological wear. They do not define destiny, but they can help track whether present health is being maintained in a way that may protect future function.

Which basic blood tests are most common to understand?

A useful starting point is to separate common tests into broad groups. The complete blood count (CBC) measures red blood cells, white blood cells, hemoglobin, and platelets. It helps identify patterns related to anemia, infection, immune activation, clotting, or bone marrow stress. Research in several settings shows that even simple complete blood count (CBC) measures can carry prognostic information, though their meaning depends heavily on the clinical setting.

Inflammation markers include C-reactive protein (CRP), which rises in many inflammatory states but is not specific to one disease. Infection-oriented markers include procalcitonin (PCT), which in human emergency department studies showed value mainly for ruling out some bloodstream infections when low, while false positives can occur in non-infectious conditions. Blood cultures are not a biomarker in the narrow sense, but they remain central because they identify actual organisms in suspected sepsis.

Other categories are more specialized. Metabolic biomarkers reflect energy and substrate use. Oxidative stress markers such as glutathione (GSH), nitrotyrosine (NT), and paraoxonase 1 (PON1) are studied in human disease, but many remain research tools rather than standard screening tests. This distinction matters when linking laboratory data to longevity.

Who may benefit most from knowing these markers?

Several groups may gain more from understanding blood markers because their baseline risk, exposure burden, or physiological reserve differs. Older adults often have more multimorbidity, medication use, and reduced resilience after infection or organ stress. In that setting, trends in hemoglobin, inflammation markers, kidney-related chemistry, or white blood cell patterns may carry more practical meaning than a single isolated value.

People with acute infection, hospitalization, chronic inflammatory disease, cancer risk, or cardiometabolic illness may also benefit from closer interpretation of blood data. Human studies in pediatric inpatients linked anemia and inflammation markers such as C-reactive protein (CRP) and leukocyte counts with nutritional risk screening. In neonatal research, complete blood count (CBC) features were associated with retinopathy risk, although the authors noted inter-observer bias and the need for prospective confirmation. In hemoglobin disorders, fasting hematologic and biochemical profiles have been examined alongside vascular measurements to understand disease burden.

A broader longevity lesson follows from these examples: the same marker can mean different things across life stages and conditions. Evidence is stronger when a test is studied repeatedly in a defined population, and weaker when findings come from small, single-setting, or exploratory analyses.

When is this knowledge most important to apply?

This knowledge is most important when blood results may change interpretation, urgency, or follow-up. Acute illness is one major setting. In suspected sepsis, time matters because delayed recognition is associated with worse outcomes. Human studies show that blood cultures remain the diagnostic reference, while rapid biomarkers such as procalcitonin (PCT) may shorten time to risk assessment. Still, available evidence also shows limits: procalcitonin (PCT) can rise in some non-infectious states, and newer whole-blood molecular methods are still developing rather than replacing standard culture methods.

It also matters during transition points in health. Examples include midlife risk assessment, the onset of unexplained fatigue, recurrent infections, nutritional decline, or monitoring after major illness. In these situations, blood markers may help distinguish transient disturbance from a pattern worth tracking over time.

For longevity, the key principle is not to wait for advanced disease before learning what common markers represent. At the same time, scientific literature supports caution against over-reading novel markers. Some are clinically established for specific uses, while others are promising but still early, population-specific, or mainly relevant in hospital-based human studies.

Tell Me More

How do lifestyle and metabolic health change blood marker meaning?

Blood markers do not act in isolation. Human cohort research in hospitalized Coronavirus Disease 2019 (COVID-19) patients found that metabolic states linked with overweight, obesity, or metabolic disorders were associated with different levels of adipokines and energy-balance hormones, including cortisol, insulin, leptin, ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and C-peptide. In that study, the primary outcome was in-hospital mortality, and severity was also grouped by World Health Organization (WHO) categories. Only cortisol remained independently associated with mortality after adjustment, while other markers tracked severity more than death risk.

For longevity, the implication is indirect. Lifestyle patterns may shape baseline inflammation, glucose handling, and stress physiology, which can alter how a test result should be interpreted. That does not mean a higher or lower marker causes faster aging by itself. It means blood data may reflect the body’s response to sleep loss, excess adiposity, illness burden, or recent stress. Scientific evidence therefore supports using patterns and context, not isolated numbers, when linking present metabolic strain with future health span.

What do newer studies suggest beyond routine blood panels?

Recent human studies suggest that multi-marker patterns may sometimes add prognostic value beyond routine clinical data, especially in acute illness. In one multicenter in vivo human study of Coronavirus Disease 2019 (COVID-19), adding metabolic biomarkers to clinical variables improved mortality prediction, even though most single markers were not independently predictive. The main reported outcome was in-hospital mortality, and the analysis also identified two biomarker phenotypes associated with disease severity but not mortality.

This matters for longevity because aging risk often emerges from interacting systems rather than one pathway alone. Still, the evidence base does not show that these advanced panels extend life or predict aging in healthy adults. The assumption comes from a broader model: persistent dysregulation in stress, inflammation, and metabolism is associated with poorer resilience over time. A major limitation is that some studies measured markers at one time point only, which can miss day-to-day biological change. That weakens causal interpretation and limits direct use for long-term forecasting.

Are inflammation and oxidative stress markers easy to overread?

Yes. Human in vivo sepsis studies show that markers such as C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), nitrotyrosine (NT), nitric oxide metabolites (NOx), oxidized low-density lipoprotein (oxLDL), and paraoxonase 1 (PON1) often move together during severe illness. In one study, higher oxidized low-density lipoprotein (oxLDL) and lower paraoxonase 1 (PON1) activity were associated with more severe sepsis, while glutathione (GSH) showed inverse correlations with several inflammatory markers. The main outcome was sepsis severity, not longevity.

A common misconception is that any elevation in an inflammation or oxidative stress marker signals chronic aging damage. That is not supported. These markers can rise with infection, trauma, medication exposure, or other temporary stressors. Another limitation is sample size: the sepsis study included a relatively small number of patients, which may increase imprecision. For longevity, these tests may be informative when repeated over time, but single abnormal values rarely justify broad conclusions about long-term decline.

Can medications or illness distort what a “bad” result means?

Often, yes. Blood markers may reflect treatment effects, disease stage, or both. In the Coronavirus Disease 2019 (COVID-19) cohort study, the authors noted that institutional dexamethasone use could partially affect biomarker interpretation, and they also acknowledged potential bias from multiple comparisons. They further stated that it remains uncertain whether measured biomarkers were involved in disease progression or were epiphenomena of a complex illness process. That distinction is important when interpreting abnormal values.

Related human research in inflammatory heart disease also shows that blood immune signals can correlate with organ-level dysfunction, yet peripheral blood still captures only part of the biology. For longevity, this means a marker may help estimate burden or resilience without fully explaining cause. Medications, acute infection, hospitalization, and organ stress can shift results in ways that do not translate to usual health status. The most defensible strategy is to interpret biomarkers as conditional signals whose meaning depends on timing, clinical context, and whether findings repeat across measurements.

Level Up

How are multi-marker blood signatures changing risk models?

## Level Up

Blood testing is moving from single markers toward pattern-based models. The idea is simple: aging and loss of resilience rarely arise from one pathway alone. They tend to reflect interacting shifts in immunity, oxidation, tissue stress, and organ reserve. In vivo human studies in sepsis support this view. Research on leukocyte surface biomarkers used flow cytometry, a method that measures proteins on immune-cell surfaces, to examine whether combined immune patterns could distinguish infection severity and predict later clinical decline. This approach matters for longevity because resilience in later life may depend less on one abnormal value and more on how several systems drift together under stress.

Still, pattern-based models need caution. In vivo human sepsis studies often focus on short-term outcomes such as clinical deterioration, organ dysfunction, or survival in hospital, not long-term aging. Some oxidative and inflammatory panels also reported very strong discrimination for sepsis severity, but those findings came from small samples and acute care settings, which may overstate performance when applied elsewhere. The scientific literature therefore supports a careful distinction: multi-marker signatures may improve risk stratification in defined clinical settings, yet their value as general longevity tools is not established. For now, their strongest role is in describing biological strain, not forecasting lifespan in healthy adults.

What does immune-cell phenotyping add beyond standard labs?

Standard blood tests count cells or measure soluble proteins, but immune-cell phenotyping asks a deeper question: what state are those cells in? In vivo human studies in suspected sepsis examined leukocyte biomarkers with flow cytometry to capture activation or suppression patterns on circulating immune cells. This matters because sepsis is not only excessive inflammation. It also includes immune exhaustion and impaired host defense. Related in vivo human pilot work measuring programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) suggests that blood may reflect this suppressed immune state, although the evidence remains early.

For longevity, the broader insight is that immune aging is partly qualitative, not just quantitative. Two people may have similar white blood cell counts but differ in how responsive or exhausted those cells are. That distinction could matter for infection recovery, tissue repair, and long-term resilience. However, current evidence is more mechanistic than outcome-based. These methods are promising for understanding why some patients deteriorate, yet they are not established screening tools for healthy aging. Limitations include specialized equipment, limited standardization, and uncertainty about how stable these phenotypes remain across time, medications, or recent illness.

Can blood markers reflect organ injury before failure appears?

Some blood markers may signal tissue injury before full organ failure becomes obvious. An important example is pancreatic stone protein/regenerating protein (PSP/Reg). In an in vivo human study of patients with sepsis in an intensive care unit, circulating pancreatic stone protein/regenerating protein (PSP/Reg) levels were higher with greater disease severity and were linked with progression toward multiple organ dysfunction syndrome (MODS). The study also measured cytokines and organ-damage markers such as creatinine, lactate dehydrogenase, and troponin I over time. This suggests that certain blood proteins may track a transition from infection to broader tissue injury.

The mechanistic support is stronger because the same research also included in vivo animal work in mice after cecal ligation and puncture, a standard sepsis model. In that model, added pancreatic stone protein/regenerating protein (PSP/Reg) was associated with worse sepsis features, which may indicate a role beyond passive correlation. Even so, animal evidence does not prove the same causal effect in humans. For longevity, the useful lesson is conceptual: future blood testing may focus more on early loss of physiological reserve than on late-stage organ failure alone. Yet this remains an acute illness application, not a validated marker of slower aging in the general population.

Why is oxidative stress testing still hard to use well?

Oxidative stress is biologically plausible in aging because reactive oxygen species and reactive nitrogen species can damage lipids, proteins, and DNA. Yet blood testing for this process remains difficult. Scientific sources note a core problem: many reactive species are unstable, so indirect markers must be used instead. In vivo human sepsis studies measured nitrotyrosine (NT), nitric oxide metabolites (NOx), oxidized low-density lipoprotein (oxLDL), paraoxonase 1 (PON1), and glutathione (GSH). These markers were associated with disease severity, and earlier human and animal studies also supported increased oxidation with reduced antioxidant capacity in sepsis.

The limitation is interpretation. A marker like oxidized low-density lipoprotein (oxLDL) may reflect lipid damage, while glutathione (GSH) reflects antioxidant defense, but neither gives a complete map of total oxidative burden. Results can also shift with acute infection, nutrition, sample handling, and timing. In one human sepsis study, several markers showed very high sensitivity and specificity, yet the sample was small and clinically heterogeneous, which may inflate apparent accuracy. For longevity, oxidative markers are best seen as research windows into stress biology, not settled standalone tests for aging rate. Their future value may depend on repeated measures, stronger standardization, and integration with immune and organ-injury signals.

Pros and Cons

Pros

• Earlier risk assessment
  ‍In vivo human sepsis studies suggest blood markers such as PCT can support faster early risk assessment than culture alone, which may matter when short-term organ injury risk is high and delayed recognition can affect near-term survival.

• Strong rule-out value
  ‍In an in vivo human emergency department study, low PCT showed about 75% sensitivity, 79% specificity, and a 98% negative predictive value at one reported cutoff, making it more useful for ruling out some bloodstream infection than confirming it.

• Tracks biological strain
  ‍Human studies in severe infection show panels including IL-6, TNF-α, oxLDL, GSH, and PON1 can reflect inflammatory and oxidative stress burden. This may help describe present physiological strain that can threaten resilience if persistent.

• Adds to standard testing
  ‍Available evidence suggests biomarkers add context to CBC, CRP, chemistries, and cultures rather than competing with them. This layered approach may improve interpretation of infection severity, organ stress, and short-term prognosis.

• Supports stewardship
  ‍In acute care, PCT-guided interpretation may help reduce unnecessary antimicrobial exposure when bacterial infection is less likely. That indirect benefit may support present health without adding avoidable treatment burden that can affect future resilience.

Cons

• Not a stand-alone test
  ‍Blood cultures remain the reference method for confirming bloodstream infection. Human studies indicate that PCT, CRP, and newer molecular or stress markers do not have enough accuracy to replace standard microbiology on their own.

• False positives occur
  ‍PCT can rise in non-infectious inflammatory states, so an abnormal result may overstate bacterial infection risk if read without symptoms, exam findings, and other labs. This limits specificity and may complicate acute decisions.

• CRP lacks specificity
  ‍CRP rises across many inflammatory states and, in human sepsis studies, did not reliably separate mild from severe disease. Its prognostic role remains debated, so isolated elevations may add uncertainty rather than clarity.

• Novel markers stay early
  ‍Oxidative stress and immune markers such as NT, NOx, neopterin, VCAM-1, ICAM-1, GSH, and PON1 are promising, but much of the evidence comes from small hospital-based human studies rather than routine longevity cohorts.

• Single values mislead
  ‍One abnormal result can reflect timing, hydration, acute stress, medication exposure, or sample variation. That can distort long-term interpretation, especially when markers are borrowed from critical care settings rather than repeated over time.

Considerations

• Context shapes meaning
  ‍The same marker may imply different risk across healthy adults, older adults, ICU patients, and people with chronic disease. Research supports interpreting results with symptoms, history, medicines, and repeat testing, not as isolated numbers.

• Human evidence is uneven
  ‍Evidence is strongest for acute infection uses such as cultures and PCT in sepsis. Links to longevity are more indirect and usually infer present resilience or physiological burden rather than predicting lifespan itself.

• Repeated trends matter
  ‍Scientific literature suggests repeated abnormalities are generally more informative than a one-time outlier. For long-term health, trend direction may matter more than one result, especially for inflammatory or oxidative stress markers.

• Access varies by test
  ‍CBC, CRP, and routine chemistry panels are widely available, while immune phenotyping, molecular tests, PSP, and oxidative stress assays often require specialized platforms. That affects feasibility, cost, and how broadly findings can be applied.

• Small-study inflation risk
  ‍Some very high sensitivity or specificity estimates for oxidative and immune markers came from small, clinically mixed sepsis samples. Such designs can overstate performance, so broader validation in humans remains an open issue.

Actionable Intelligence

Innovative Tips

• Serial PCT Trend
  ‍In vivo human: PCT at 0, 24, 48 h may aid rule-out; benefit remains acute-care specific.
  ‍
• Culture Plus Biomarker
  ‍Human studies paired cultures with same-draw PCT once; faster context, not culture replacement.
  ‍
• Morning Marker Series
  ‍In vivo human: ICU work sampled 06:00–12:00 over 7 days; trend use is still early.
  ‍
• ‍Oxidative Stress Panel
  ‍In vivo human: GSH, oxLDL, PON1 sampled once may reflect acute strain; not aging proof.
  ‍
• Inflammation Clusters
  ‍In vivo human: IL-6, TNF-α, CRP patterns may map severity; longevity use is unproven.
  ‍
• Immune Adhesion Readout
  ‍In vivo human: VCAM-1 and ICAM-1 with sepsis panels remain exploratory, mainly hospital-based.
  ‍
• Neopterin Add-On
  ‍In vivo human: neopterin rose in mild and severe sepsis; broader utility is not established.
  ‍
• PSP Time-Course
  ‍In vivo human: PSP at admission, 72 h, day 5, day 7 may track injury; still early.
  ‍
• Whole-Blood Molecular
  ‍Human studies examine direct whole-blood pathogen tests; speed may improve, accuracy still limits use.
  ‍
• Same-Day Context Log
  ‍Other evidence: note illness, drugs, fasting, and draw time once per test; may reduce misreadings.

‍

Convergent and Divergent Viewpoints

Convergents

• Blood cultures remain the reference test in suspected bloodstream infection
  ‍In vivo human evidence supports cultures as the confirmation standard; biomarkers may add speed, not replacement. This matters for longevity because missed sepsis can threaten later organ reserve and survival.

• Procalcitonin is mainly useful as an adjunct for early sepsis assessment
  ‍In vivo human studies and reviews agree PCT may support earlier risk assessment when bacterial sepsis is suspected, especially in emergency care, but interpretation still depends on symptoms, exam, and other labs.

• Low procalcitonin has stronger rule-out than rule-in value
  ‍In vivo human ED evidence found a cutoff near 0.15 ng/mL gave about 75% sensitivity, 79% specificity, and 98% negative predictive value, so low PCT is more informative for exclusion than confirmation.

• Biomarkers are most defensible when layered onto standard testing
  ‍Clinical and review evidence broadly agree that CBC, chemistry, CRP, cultures, and selective biomarkers work best together. For long-term health, this reduces overreading of any single abnormal value.

• Inflammatory and oxidative markers reflect acute biological strain in sepsis
  ‍In vivo human studies link IL-6, TNF-α, neopterin, oxLDL, NOx, GSH, and PON1 with sepsis severity. Their main established role is acute severity mapping, not direct measurement of aging pace.

• Context and repeat measurement matter more than one isolated value
  ‍Across the evidence base, marker meaning shifts with acute illness, timing, and clinical state. For longevity, repeated abnormalities are generally more informative than a single stressed sample.

• CRP is a broad inflammation marker, not a specific severity gauge
  ‍In vivo human sepsis data indicate CRP rises with inflammation but may not separate mild from severe sepsis well. It may support context, yet it has limited specificity for high-stakes interpretation.

• Rapid molecular methods are promising but not yet substitutes for culture
  ‍In vivo human and clinical implementation evidence agree faster pathogen detection may shorten time to identification, but current whole-blood or culture-linked molecular assays do not fully replace standard microbiology.

• Novel markers such as PSP appear promising but remain early
  ‍In vivo human studies suggest PSP may track sepsis severity and prognosis earlier than some conventional markers, yet current use remains hospital-based and not established for routine longevity assessment.

Divergent

• How much weight should be given to one procalcitonin cutoff
  ‍Some researchers favor thresholds near 0.10-0.15 ng/mL for rapid triage, while others argue cutoffs vary by setting and assay. The debate reflects trade-offs between false reassurance and unnecessary escalation.

• Whether procalcitonin should guide antimicrobial intensity or mainly inform diagnosis
  ‍Some researchers say PCT meaningfully supports stewardship and follow-up decisions; others say noninfectious elevations limit decision weight. The disagreement is practical, not about whether PCT changes during infection.

• How far oxidative stress panels are ready for broader clinical use
  ‍Some researchers view oxLDL, GSH, PON1, and NT as useful severity tools; others argue small samples and mixed patient features may inflate accuracy. This affects whether panels stay research-focused or expand clinically.

• Whether pancreatic stone protein truly outperforms older markers
  ‍Some researchers argue PSP rises earlier and predicts MODS or mortality better than CRP or PCT; others say evidence is still too ICU-specific and not yet stable across infections or care environments.

• How to interpret very high discrimination estimates from small sepsis cohorts
  ‍Some researchers treat near-perfect ROC findings as strong signal; others argue sample size, heterogeneity, and timing may overstate performance. This debate matters before translating marker panels into routine use.

• Whether newer biomarker panels improve outcomes or only prediction
  ‍Some researchers say faster multi-marker risk models may improve care by shortening recognition time; others say better prediction does not automatically improve survival without proven management changes.

• How directly acute biomarker severity maps onto longevity relevance
  ‍Some researchers argue severe inflammatory burden informs future resilience after critical illness; others say acute prognostic markers should not be extended to aging biology without long-term human follow-up.

Longevity Index

70/100

Definition

• Critical markers
  ‍Laboratory measures taken from blood that are linked to important biological processes such as inflammation, infection, oxygen transport, kidney stress, or metabolic balance.

• Marker
  ‍Any measurable feature linked to a biological process.

• Complete blood count (CBC)
  ‍A routine blood test panel that measures red blood cells, white blood cells, hemoglobin, and platelets.

• C-reactive protein (CRP)
  ‍An inflammation marker that rises in many inflammatory states but is not specific to one disease.

• Procalcitonin (PCT)
  ‍An infection-oriented blood marker that may help interpret whether bacterial infection is likely and is mainly useful for ruling out some bloodstream infections when low.

• Blood cultures
  ‍The reference method for confirming bloodstream infection because they identify actual organisms in suspected sepsis.

• Inflammation
  ‍A biological response to infection, injury, or other stress that can raise markers such as CRP, IL-6, and TNF-α.

• Chronic inflammation
  ‍Ongoing inflammation over time that may be tied to processes shaping aging outcomes.

• Oxidative stress
  ‍A biological state in which reactive oxygen species and reactive nitrogen species can damage lipids, proteins, and DNA.

• Oxidative markers
  ‍Blood markers used to reflect oxidative stress burden, such as oxLDL, GSH, NT, NOx, and PON1.

• Interleukin-6 (IL-6)
  ‍An inflammatory signaling molecule associated with illness severity in sepsis studies.

• Tumor necrosis factor alpha (TNF-α)
  ‍An inflammatory signaling molecule associated with illness severity in sepsis studies.

• Oxidized low-density lipoprotein (oxLDL)
  ‍A marker that reflects lipid damage from oxidative stress and was associated with more severe sepsis in human studies.

• Glutathione (GSH)
  ‍A marker of antioxidant defense that showed inverse correlations with several inflammatory markers in sepsis studies.

• Nitrotyrosine (NT)
  ‍An oxidative stress marker used as an indirect measure of reactive nitrogen-related damage.

• Paraoxonase 1 (PON1)
  ‍An enzyme-related oxidative stress marker whose lower activity was associated with more severe sepsis in one human study.

• Nitric oxide metabolites (NOx)
  ‍Indirect blood markers used to reflect nitric oxide-related oxidative or inflammatory activity.

• Biomarker
  ‍A measurable biological signal used to reflect a process such as inflammation, infection, metabolism, immune activity, or organ injury.

• Metabolic biomarkers
  ‍Markers that reflect energy and substrate use, and in some studies were added to clinical variables to improve prediction in acute illness.

• Adipokines
  ‍Hormone-like signals related to body fat and metabolic state.

• Cortisol
  ‍A stress-related hormone that in one hospitalized COVID-19 cohort remained independently associated with mortality after adjustment.

• Insulin
  ‍A hormone involved in glucose handling and metabolic regulation.

• Leptin
  ‍An energy-balance hormone linked to body fat and metabolic state.

• Ghrelin
  ‍An energy-balance hormone involved in appetite and metabolic signaling.

• Glucagon-like peptide-1 (GLP-1)
  ‍A hormone involved in glucose regulation and energy balance.

• Peptide YY (PYY)
  ‍A gut-derived hormone involved in appetite and energy-balance signaling.

• C-peptide
  ‍A blood marker related to insulin production and metabolic state.

• World Health Organization (WHO) categories
  ‍Severity groupings used in one COVID-19 study to classify illness severity.

• In-hospital mortality
  ‍Death occurring during a hospital admission; a short-term prognostic outcome commonly used in acute illness studies.

• Prognostic
  ‍Used to describe information that helps estimate future clinical outcomes such as severity, deterioration, or short-term risk.

• Risk stratification
  ‍The process of grouping patients by likelihood of worse outcomes using clinical data, biomarkers, or both.

• Sepsis
  ‍A severe condition in which infection is associated with major body-wide biological stress and can progress to organ dysfunction.

• Bacteremia
  ‍The presence of bacteria in the bloodstream.

• Microbiology
  ‍The laboratory field that identifies organisms such as bacteria in samples including blood cultures.

• Whole-blood molecular methods
  ‍Newer laboratory methods that aim to detect pathogens directly from blood more quickly, though they are still developing and do not replace standard culture methods.

• Flow cytometry
  ‍A laboratory method that measures proteins on immune-cell surfaces to examine immune patterns such as activation or suppression.

• Leukocyte
  ‍A white blood cell.

• Leukocyte surface biomarkers
  ‍Proteins found on white blood cell surfaces that can be measured to assess immune-cell state.

• Immune-cell phenotyping
  ‍A method of characterizing what state immune cells are in, rather than only counting them or measuring soluble proteins.

• Immune exhaustion
  ‍A suppressed or less responsive immune state that can occur in severe illness such as sepsis.

• Host defense
  ‍The body’s ability to resist and control infection.

• Programmed death 1 (PD-1)
  ‍An immune regulatory protein studied as a blood signal of suppressed immune state.

• Programmed death ligand 1 (PD-L1)
  ‍A binding partner of PD-1 studied as a blood signal of suppressed immune state.

• Pancreatic stone protein/regenerating protein (PSP/Reg)
  ‍A circulating blood protein studied in sepsis that was higher with greater disease severity and linked with progression toward multiple organ dysfunction syndrome.

• Multiple organ dysfunction syndrome (MODS)
  ‍A severe clinical state in which dysfunction develops in multiple organs.

• Cytokines
  ‍Cell-signaling proteins involved in immune and inflammatory responses.

• Creatinine
  ‍A blood marker commonly used to reflect kidney-related function or stress.

• Lactate dehydrogenase
  ‍A blood marker of tissue injury or cell damage.

• Troponin I
  ‍A blood marker associated with heart muscle injury.

• Cecal ligation and puncture
  ‍A standard animal sepsis model used in mice to study severe infection and its biological effects.

• Physiological reserve
  ‍The body’s capacity to tolerate stress, illness, or injury before function declines.

• Reactive oxygen species
  ‍Highly reactive molecules that can contribute to oxidative damage.

• Reactive nitrogen species
  ‍Highly reactive nitrogen-containing molecules that can contribute to oxidative or nitrosative damage.

• Antioxidant capacity
  ‍The body’s ability to neutralize oxidative stress.

• Hemoglobin
  ‍The oxygen-carrying protein measured in a CBC.

• Platelets
  ‍Blood cell fragments measured in a CBC that are involved in clotting.

• Bone marrow stress
  ‍A strain state affecting the tissue that produces blood cells, sometimes suggested by CBC patterns.

• Leukocyte counts
  ‍White blood cell counts measured in blood testing.

• Hematologic
  ‍Related to blood cells and blood-forming tissues.

• Biochemical profiles
  ‍Sets of blood chemistry measurements used to assess body function or disease burden.

• Retinopathy
  ‍Disease affecting the retina; in the provided context it appeared in neonatal research as an outcome associated with CBC features.

• Prospective confirmation
  ‍Confirmation in future, forward-looking studies rather than relying only on earlier or retrospective findings.

• Inter-observer bias
  ‍Variation in findings caused by differences between observers measuring or interpreting results.

• Multimorbidity
  ‍The presence of multiple health conditions in the same person.

• Cardiometabolic illness
  ‍Disease involving both cardiovascular and metabolic health.

• Dexamethasone
  ‍A medication noted in one COVID-19 study as a possible influence on biomarker interpretation.

• Multiple comparisons
  ‍A statistical issue in which testing many associations can increase the chance of misleading findings.

• Epiphenomena
  ‍Measured features that accompany a disease process without necessarily causing it.

• Peripheral blood
  ‍Blood circulating in the body that is sampled for laboratory testing.

• Clinical deterioration
  ‍Worsening of a patient’s condition over time.

• Organ dysfunction
  ‍Impaired function of an organ, often used as an outcome in severe illness studies.

• Phenotype
  ‍A recognizable pattern or grouping of biological features; in this context, biomarker patterns associated with disease severity.

• Specificity
  ‍A test’s ability to correctly identify people who do not have a condition.

• Sensitivity
  ‍A test’s ability to correctly identify people who do have a condition.

• Negative predictive value
  ‍The likelihood that a negative test result truly means the condition is absent in the studied setting.

• Cutoff
  ‍A chosen test threshold used to classify a result as positive, negative, or higher risk.

• Neopterin
  ‍An immune-related marker that rose in mild and severe sepsis in one in vivo human context.

• VCAM-1
  ‍Vascular cell adhesion molecule 1, an immune adhesion-related marker described as exploratory and mainly hospital-based.

• ICAM-1
  ‍Intercellular adhesion molecule 1, an immune adhesion-related marker described as exploratory and mainly hospital-based.

• Acute care
  ‍Medical care for short-term severe illness, such as emergency or intensive hospital care.

• ICU
  ‍Intensive care unit, a hospital setting for critically ill patients.

• Rule-out value
  ‍The usefulness of a test for making a condition less likely when the result is low or negative.

• Rule-in value
  ‍The usefulness of a test for confirming a condition when the result is high or positive.

• Clinical setting
  ‍The specific healthcare context in which a test is used, such as healthy adults, emergency departments, or ICU patients.

• Hospital-based human studies
  ‍Human studies conducted in hospitalized patients, often focused on acute illness rather than healthy aging.

• Standardization
  ‍The process of making measurement methods more consistent across settings and over time.

• Clinical consensus
  ‍Broad agreement in medical practice or interpretation based on available evidence.

‍